REVIEW article
Front. Endocrinol.
Sec. Clinical Diabetes
Volume 16 - 2025 | doi: 10.3389/fendo.2025.1710511
This article is part of the Research TopicCommunity and Clinical Pharmacy Services in Type 2 Diabetes Care: Volume IIView all 4 articles
NEW APPROACH TO OPTIMIZE THERAPY IN TYPE 2 DIABETES MELLITUS: THE IMPORTANCE OF SUBCLASSIFICATION
Provisionally accepted
María José Reyes-Medina1,2,3
Vanesa Cantón Habas1,2,3*Francisco Javier Sánchez-Jiménez1,2,3Enrique Molina-Hurtado4
María del Pilar Carrera-González2,5- 1University of Cordoba, Córdoba, Spain
- 2Instituto Maimonides de Investigacion Biomedica de Cordoba, Córdoba, Spain
- 3Hospital Universitario Reina Sofia, Córdoba, Spain
- 4Servicio Andaluz de Salud Area de Gestion Sanitaria Sur de Cordoba, Cabra, Spain
- 5Universidad de Jaen, Jaén, Spain
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Despite advances in diagnosis, monitoring, and pharmacological treatment, type 2 diabetes mellitus continues to be associated with a high number of serious microvascular and macrovascular complications. The objective of this review was to explore the usefulness of subclassification based on patient pathophysiology, its implementation in clinical practice, and its potential to tailor available treatments based on the patient's pathophysiological profile, in order to evaluate personalized alternatives that optimize the management of this complex disease. In this sense, patients with recently diagnosed type 2 diabetes mellitus could be grouped into seven subgroups: diabetes with pancreatic β-cell deficiency, insulin-resistant diabetes, patients with a combination of deficient insulin secretion and increased resistance, obesity-related diabetes, patients with obesity and a high level of insulin resistance, age-related diabetes, and diabetes with hereditary components. A new algorithm for the stratified diagnostic classification of type 2 diabetes mellitus is presented. According to the reviewed and currently available studies on oral antidiabetics, some drugs may be more effective than others depending on the patient's subgroup. We propose the administration of insulin or secretagogues in pancreatic β-cell deficiency, thiazolidinediones, SGLT-2 inhibitors or GLP-1 receptor agonists in insulin resistance, and GIP/GLP-1 receptor agonists, GLP-1 receptor agonists or DPP-4 inhibitors depending on the body mass index and the associated risk of hepatic steatosis. Metformin remains recommended as the first-line universal agent across all patient subgroups.
Keywords: type 2 diabetes, New subgroups, Cluster analysis, treatment algorithm 2024, Insulin Resistance, beta cell deficiency
Received: 22 Sep 2025; Accepted: 10 Oct 2025.
Copyright: © 2025 Reyes-Medina, Cantón Habas, Sánchez-Jiménez, Molina-Hurtado and Carrera-González. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Vanesa Cantón Habas, n92cahav@uco.es
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.